PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
2.20
Concerning net debt at 1.25-1.5x Biotechnology median of 1.66. Martin Whitman would look for hidden assets or restructuring potential.
No Data
No Data available this quarter, please select a different quarter.
3.37
Current ratio near Biotechnology median of 3.60. David Dodd would examine if industry-standard liquidity is appropriate given business model.
No Data
No Data available this quarter, please select a different quarter.